Adipomyobiology Of Obesity And Related Diseases: Therapy Insights

Abstract

Today, the most widespread disease around the world is not COVID-19 or any other communicable disease. Indeed, obesity and type 2 diabetes mellitus (T2DM) have been recognized as the main risks for cardiometabolic diseases (CMD) and their morbidity and mortality signature. Recent studies revealed that the adipose tissue and the skeletal muscles may function as endocrine and paracrine organs secreting multiple proteins termed adipokines and myokines respectively. Some of them being produced both by adipose and skeletal tissue, hence dubbed adipomyokines. The contents of this review highlights the following two topics: (i) the progress in knowledge of adipomyokines may lead to better understandings of the process of pathogenesis of obesity and related CMD, and (ii) in-depth studies on Palade-Blobel’s general theory of cell protein secretion may allow to explore its pharmacological potentials for new therapies of these diseases. This may open up an intriguing line of scientific enquiry that will unite adipobiologists and myobiologists in the fight against obesity and related CMD.